Oncotarget

Research Papers:

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma

Scott A. Ezell _, Michele Mayo, Teeru Bihani, Suprawee Tepsuporn, Suping Wang, Melissa Passino, Shaun E. Grosskurth, Mike Collins, Julie Parmentier, Corinne Reimer and Kate F. Byth

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:4990-5001. https://doi.org/10.18632/oncotarget.2071

Metrics: PDF 2933 views  |   HTML 2079 views  |   ?  


Abstract

Scott A. Ezell1, Michele Mayo1, Teeru Bihani1, Suprawee Tepsuporn1, Suping Wang1, Melissa Passino1, Shaun E. Grosskurth1, Mike Collins1, Julie Parmentier1, Corinne Reimer1 and Kate F. Byth1

1 AstraZeneca R&D Boston, Waltham, Massachusetts

Correspondence:

Kate F Byth, email:

Keywords: Ibrutinib, BTK, AZD2014, mTOR, DLBCL

Received: May 11, 2014 Accepted: June 5, 2014 Published: June 7, 2014

Abstract

Diffuse large B cell lymphoma is generally treated by chemotherapy and there is an unmet medical need for novel targeted therapies or combination therapies. Using in vitro screening, we have identified the combination of ibrutinib, an inhibitor of the tyrosine kinase BTK, and AZD2014, an mTOR catalytic inhibitor, as being highly synergistic in killing ABC-subtype DLBCL cell lines. Simultaneous inhibition of BTK and mTOR causes apoptosis both in vitro and in vivo and results in tumor regression in a xenograft model. We identify two parallel mechanisms that underlie apoptosis in this setting: cooperative inhibition of cap-dependent translation, and the inhibition of an NF-κB/IL10/STAT3 autocrine loop. Combined disruption of these pathways is required for apoptosis. These data represent a rational basis for the dual inhibition of BTK and mTOR as a potential treatment for ABC-subtype DLBCL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2071